David Donabedian

President and CEO at Newleos Therapeutics.

Raised on Newleos Therapeutics filings

$93.4M

of $93.4M offered across 1 Form D filing

Company

Biotech · Boston, MA

Drugs for anxiety and substance use disorders

Drugs for anxiety and substance use disorders

Newleos Therapeutics Form D filings
Filed	Security	Sold of offered	Filing
Feb 24, 2025	Equity	$93.4M/ $93.4M	Form D

Also named on Newleos Therapeutics filings